Moderna, Inc. to Post FY2022 Earnings of $21.61 Per Share, SVB Leerink Forecasts (NASDAQ:MRNA)

Moderna, Inc. (NASDAQ:MRNAGet Rating) – Investment analysts at SVB Leerink raised their FY2022 earnings estimates for shares of Moderna in a research report issued on Tuesday, January 17th. SVB Leerink analyst M. Foroohar now anticipates that the company will post earnings per share of $21.61 for the year, up from their previous estimate of $19.43. SVB Leerink has a “Market Perform” rating and a $111.00 price target on the stock. The consensus estimate for Moderna’s current full-year earnings is $21.16 per share. SVB Leerink also issued estimates for Moderna’s Q4 2022 earnings at $5.14 EPS, Q1 2023 earnings at $2.55 EPS, Q2 2023 earnings at $2.54 EPS, Q4 2023 earnings at $2.51 EPS, FY2023 earnings at $10.13 EPS and FY2024 earnings at $11.01 EPS.

Moderna (NASDAQ:MRNAGet Rating) last announced its quarterly earnings data on Thursday, November 3rd. The company reported $2.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.04 by ($0.51). The firm had revenue of $3.36 billion during the quarter, compared to the consensus estimate of $3.33 billion. Moderna had a net margin of 55.00% and a return on equity of 70.03%.

Several other research firms have also issued reports on MRNA. Piper Sandler boosted their target price on shares of Moderna from $214.00 to $217.00 and gave the company an “overweight” rating in a report on Tuesday, December 20th. Cowen reduced their target price on shares of Moderna from $165.00 to $145.00 in a research report on Thursday, October 20th. The Goldman Sachs Group upped their price target on shares of Moderna from $290.00 to $296.00 and gave the company a “buy” rating in a research note on Thursday, October 13th. JPMorgan Chase & Co. lowered their target price on shares of Moderna from $165.00 to $122.00 and set a “neutral” rating on the stock in a research note on Monday, October 24th. Finally, Chardan Capital raised their price objective on shares of Moderna from $191.00 to $208.00 and gave the company a “neutral” rating in a research report on Wednesday. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $194.00.

Moderna Stock Performance

Shares of Moderna stock opened at $193.98 on Friday. The company has a quick ratio of 1.80, a current ratio of 2.10 and a debt-to-equity ratio of 0.05. Moderna has a twelve month low of $115.03 and a twelve month high of $217.25. The stock has a market cap of $74.52 billion, a price-to-earnings ratio of 7.02 and a beta of 1.71. The company’s fifty day moving average is $185.39 and its 200 day moving average is $160.91.

Insider Transactions at Moderna

In other Moderna news, CEO Stephane Bancel sold 40,000 shares of the stock in a transaction dated Thursday, January 19th. The shares were sold at an average price of $192.06, for a total transaction of $7,682,400.00. Following the transaction, the chief executive officer now directly owns 5,411,946 shares in the company, valued at approximately $1,039,418,348.76. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Moderna news, CEO Stephane Bancel sold 40,000 shares of the stock in a transaction dated Thursday, January 19th. The shares were sold at an average price of $192.06, for a total transaction of $7,682,400.00. Following the completion of the sale, the chief executive officer now directly owns 5,411,946 shares of the company’s stock, valued at $1,039,418,348.76. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Noubar Afeyan sold 10,000 shares of the stock in a transaction dated Wednesday, January 18th. The shares were sold at an average price of $200.20, for a total transaction of $2,002,000.00. Following the sale, the director now directly owns 2,247,209 shares of the company’s stock, valued at $449,891,241.80. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 495,899 shares of company stock worth $87,285,286. Insiders own 17.30% of the company’s stock.

Hedge Funds Weigh In On Moderna

A number of institutional investors have recently bought and sold shares of MRNA. Price T Rowe Associates Inc. MD raised its position in Moderna by 89.9% during the 3rd quarter. Price T Rowe Associates Inc. MD now owns 6,443,409 shares of the company’s stock worth $761,934,000 after buying an additional 3,051,035 shares during the last quarter. Renaissance Technologies LLC raised its position in Moderna by 108.2% during the 1st quarter. Renaissance Technologies LLC now owns 3,818,180 shares of the company’s stock worth $657,720,000 after buying an additional 1,984,458 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Moderna by 67.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,105,551 shares of the company’s stock worth $248,978,000 after buying an additional 847,329 shares during the last quarter. FMR LLC raised its position in Moderna by 20.5% during the 2nd quarter. FMR LLC now owns 2,706,654 shares of the company’s stock worth $386,645,000 after buying an additional 459,992 shares during the last quarter. Finally, Invesco Ltd. raised its position in Moderna by 21.1% during the 1st quarter. Invesco Ltd. now owns 2,128,252 shares of the company’s stock worth $366,611,000 after buying an additional 371,311 shares during the last quarter. 63.11% of the stock is owned by hedge funds and other institutional investors.

About Moderna

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Further Reading

Earnings History and Estimates for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.